Transcriptome analysis and safety profile of the early-phase clinical response to an adjuvanted grass allergoid immunotherapy

BACKGROUND: Specific immunotherapy is the only type of disease-modifying treatment, which induces rapid desensitization and long-term sustained unresponsiveness in patients with seasonal allergic rhinoconjunctivitis. The safety and tolerability of a new cumulative dose regimen of 35600 SU Grass MATA...

Descripción completa

Detalles Bibliográficos
Autores principales: Starchenka, Sviatlana, Heath, Matthew D., Lineberry, Alyson, Higenbottam, Tim, Skinner, Murray A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872854/
https://www.ncbi.nlm.nih.gov/pubmed/31768216
http://dx.doi.org/10.1016/j.waojou.2019.100087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872854/
https://www.ncbi.nlm.nih.gov/pubmed/31768216
http://dx.doi.org/10.1016/j.waojou.2019.100087

Ejemplares similares